NCT05645627CompletedPhase 3
A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis
A Phase Ⅲ, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of IBI112 in Different Dose Regimens for the Treatment of Subjects With Moderate-to-severe Plaque Psoriasis
Source: ClinicalTrials.gov · Last updated 29 Oct 2024
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of participants with moderate to severe plaque-type psoriasis.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 500 (actual)
- First submitted
- 1 Dec 2022
- Start date
- 10 Feb 2023
- Primary completion date
- 9 Aug 2023
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Diseases
- Psoriasis
- NCT number
- NCT05645627
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 500
- From 10 Feb 2023 to the primary completion date, 9 Aug 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has received any therapeutic agent directly targeted to IL-17within 6 months of the first administration of study agent
- Has received any therapeutic agent directly targeted toTNF-a within 3 months of the first administration of study agent
- Has received any conventional therapeutic agent within 1 months of the first administration of study agent
- Has received any topic therapeutic agent within 2 weeks of the first administration of study agent
Other illness
- History of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease
- Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis
Who the study is looking for
- Diagnosis of plaque-type psoriasis with or without psoriatic arthritis for at least 6 months prior to first administration of any study agent
- Must be a candidate for phototherapy or systemic treatment for psoriasis (either new to treatment or having had previous treatment)
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Skin Disease Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.